WP
DNLI icon

Woodline Partners’s Denali Therapeutics DNLI Stock Holding History

Woodline Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.99M Buy
364,082
+250,000
+219% +$4.97M 0.03% 594
2025
Q4 		$1.88M Buy
114,082
+565
+0.5% +$9.54K 0.01% 776
2025
Q3 		$1.65M Hold
113,517
– – 0.01% 748
2025
Q2 		$1.59M Hold
113,517
– – 0.01% 757
2025
Q1 		$1.54M Buy
113,517
+13,517
+14% +$259K 0.01% 706
2024
Q4 		$2.04M Buy
+100,000
New +$2.56M 0.01% 645
2024
Q3 		– Sell
-56,554
Closed -$1.31M – 625
2024
Q2 		$1.31M Sell
56,554
-452,011
-89% -$8.68M 0.01% 447
2024
Q1 		$10.4M Buy
508,565
+310,981
+157% +$5.84M 0.1% 262
2023
Q4 		$4.24M Sell
197,584
-653,905
-77% -$13M 0.05% 333
2023
Q3 		$17.6M Buy
851,489
+739,277
+659% +$18.8M 0.21% 146
2023
Q2 		$3.31M Buy
112,212
+11,901
+12% +$335K 0.04% 359
2023
Q1 		$2.31M Buy
+100,311
New +$2.76M 0.03% 400
2022
Q4 		– Sell
-444,256
Closed -$13.6M – 778
2022
Q3 		$13.6M Buy
444,256
+263,284
+145% +$8.56M 0.19% 156
2022
Q2 		$5.33M Sell
180,972
-75,706
-29% -$1.98M 0.08% 251
2022
Q1 		$8.26M Buy
256,678
+204,224
+389% +$7.03M 0.13% 189
2021
Q4 		$2.34M Buy
+52,454
New +$2.49M 0.03% 399

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Woodline Partners's DNLI Position: Q1 2026 in Review

Woodline Partners increased its Denali Therapeutics (DNLI) stake by 219% in Q1 2026, buying an estimated $4.97M and bringing the position to 364,082 shares worth $6.99M. The position accounts for 0.03% of the portfolio, ranked #594.

Woodline Partners first reported a position in DNLI in Q4 2021 and has held it in 16 quarters since. The position peaked at $17.6M in Q3 2023. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Woodline Partners held 364,082 shares of Denali Therapeutics worth $6.99M as of Q1 2026.
  • Woodline Partners bought 250,000 Denali Therapeutics shares in Q1 2026, an estimated $4.97M.
  • Denali Therapeutics made up 0.03% of Woodline Partners's portfolio in Q1 2026, its #594 holding.
  • Woodline Partners first reported a position in Denali Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • Woodline Partners's Denali Therapeutics position peaked at $17.6M in Q3 2023.
  • 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.